Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cellgram-DC in Advanced or Recurrent Epithelial Ovarian Cancer
NCT04614051Phase 1Terminated
- Sponsor
- Pharmicell Co., Ltd.
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cellgram-DC-PC in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Pharmicell Co., Ltd. Primary endpoint: Adverse Events at 28 weeks. Started Feb 2022; status: terminated.
02
Drugs
Cellgram-DC-PC
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04614051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04614051.